Drugs & Therapy Perspectives

, Volume 6, Issue 3, pp 7–9 | Cite as

Preliminary data indicate a place for candoxatril in the early treatment of CHF

New Drugs and Therapeutic
  • 6 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    MacPherson S. Candoxatril leads the way as new treatment for mild CHF. Inpharma 1995; (984): 9-210Google Scholar
  2. 2.
    Richards M, Espiner E, Frampton C, et al. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension 1990; 16(3): 269–76.Google Scholar
  3. 3.
    Richards AM, Wittert G, Espiner EA, et al. Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects. J Hypertens 1991; 9(10): 955–62PubMedCrossRefGoogle Scholar
  4. 4.
    Connell JMC, Jardine AG, Northridge DB. Therapeutic use of atrial natriuretic factor. Br J Clin Pharmacol 1992; 34: 102–5PubMedCrossRefGoogle Scholar
  5. 5.
    Motwani JG, Lang CC, Allen MJ, et al. Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure. Clin Pharmacol Ther 1993; 54: 661–9PubMedCrossRefGoogle Scholar
  6. 6.
    O’Connell JE, Jardine AG, Davidson G, et al. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992; 10(3): 271–7PubMedCrossRefGoogle Scholar
  7. 7.
    Manivannan A, Taylor D, Jackson N. Effect of UK-79, 300, an atriopeptidase inhibitor on plasma atrial natriuretic factor in chronic heart failure [abstract]. Circulation 1990; 82 (4 Suppl. III): III–386Google Scholar
  8. 8.
    Eisner D, Müntze A, Kromer EP, et al. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992; 70: 494–8CrossRefGoogle Scholar
  9. 9.
    Riegger AJG, Keck M, Kentsch M, et al. Double-blind randomized multicenter study to compare the hemodynamic effects of candoxatril with placebo in patients with chronic heart failure [abstract]. Eur Heart J 1993 Aug; 14 Suppl: 119Google Scholar
  10. 10.
    Metcalfe MJ, Northridge DB, Henderson E, et al. Comparison of a new neutral endopeptidase inhibitor with frusemide in left ventricular dysfunction [abstract]. Br Heart J 1991 Jul; 66: 69Google Scholar
  11. 11.
    Northridge DB, Metcalfe MJ, Jackson NC, et al. Neutral endopeptidase inhibition versus frusemide in mild heart failure: diuretic, haemodynamic and neuroendocrine effects [abstract]. Eur Heart J 1991 Aug; 12 Suppl.: 374Google Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations